Tuberous Sclerosis Complex (TSC)

Tuberous sclerosis complex (TSC) is a rare genetic disorder that causes benign (non-cancerous) tumor-like growths called hamartomas to form in the brain, skin, kidneys, heart, and lungs. Despite being non-malignant, these growths can profoundly disrupt the organs they grow in — causing epilepsy, intellectual disability, autism, kidney failure, and lung disease. TSC affects roughly 1 in 6,000 to 10,000 people worldwide, including about 50,000 Americans and 1 million people globally. It was first described in 1880 by French neurologist Désiré-Magloire Bourneville, who used the evocative name "tuberose sclerosis" (hardened potato-like lumps) to describe the brain lesions he found at autopsy. Today, powerful medications called mTOR inhibitors — including everolimus and sirolimus — have genuinely changed the course of this disease by targeting its root molecular cause.

  1. Overview: What Is Tuberous Sclerosis Complex?
  2. TSC1 and TSC2: The mTOR Connection
  3. Brain Manifestations: Tubers, Nodules, and Astrocytomas
  4. Epilepsy and Infantile Spasms
  5. Skin Features: Diagnosis You Can See
  6. Cardiac, Renal, and Pulmonary Involvement
  7. Diagnosis: Clinical Criteria and Testing
  8. mTOR Inhibitors: Everolimus and Sirolimus
  9. Seizure Management and Epilepsy Surgery
  10. Surveillance and Monitoring Protocol
  11. Key Research Papers
  12. Featured Videos
  13. Connections

Overview: What Is Tuberous Sclerosis Complex?

Tuberous sclerosis complex is an autosomal dominant disorder, meaning a single mutated copy of the responsible gene is enough to cause the disease. Each child born to a parent with TSC has a 50% chance of inheriting it. However, in roughly two-thirds of all TSC cases, the mutation arises completely fresh — called a de novo mutation — in a child with no family history of the condition. This explains why TSC can appear unexpectedly in otherwise unaffected families.

The word "complex" in the name reflects the disorder's extraordinary breadth. TSC is not simply a brain disease or a skin disease or a kidney disease — it is all of these and more, simultaneously. The hallmark lesions are hamartomas: overgrowths of disorganized but non-cancerous tissue. Hamartomas form because cells in affected tissues lose their normal brakes on growth. In the brain these become cortical tubers. In the skin they appear as distinctive birthmarks and papules. In the kidneys they grow into angiomyolipomas. In the heart they form cardiac rhabdomyomas — tumors that are often detectable even before birth on fetal ultrasound.

No two people with TSC are affected in exactly the same way. Some individuals have mild skin findings and well-controlled seizures and live largely independently. Others have severe intellectual disability, treatment-resistant epilepsy, and life-threatening kidney or lung involvement. This variability — even within the same family carrying the same mutation — makes TSC one of the most clinically unpredictable genetic conditions in medicine.

The discovery that TSC is caused by malfunction of the mTOR (mechanistic target of rapamycin) pathway — the master regulator of cell growth and metabolism — was a turning point. It meant that existing drugs (rapamycin and its analogues) could, for the first time, actually target the molecular root of the disease. Everolimus (brand name Afinitor) is now FDA-approved for three separate TSC indications, representing a genuine breakthrough for a disease that had previously been managed only symptom by symptom.

Back to Table of Contents

TSC1 and TSC2: The mTOR Connection

TSC is caused by loss-of-function mutations in one of two tumor suppressor genes:

Under normal circumstances, the hamartin and tuberin proteins form a complex together (the TSC1–TSC2 complex) that acts as a powerful brake on the mTOR pathway. Think of mTOR as the gas pedal of a cell: it drives growth, protein synthesis, and cell division. The TSC1–TSC2 complex keeps that gas pedal under control. When either hamartin or tuberin is defective due to a mutation, this brake is lost — the gas pedal stays floored — and cells grow and proliferate in an uncontrolled way. The result is hamartoma formation throughout the body.

The biochemistry is elegant and explains exactly why mTOR inhibitor drugs work in TSC. The TSC1–TSC2 complex normally inhibits a small GTPase called Rheb, which in turn activates mTORC1 (mTOR complex 1). Without functional TSC1/TSC2, Rheb is chronically active, mTORC1 is chronically hyperactivated, and cells receive a constant signal to grow. Everolimus and sirolimus both directly inhibit mTORC1 — pharmacologically replacing the function of the missing TSC complex.

Importantly, cells in TSC follow the classical "two-hit" model of tumor suppressor gene inactivation: a person inherits one mutant copy of TSC1 or TSC2 in every cell, but hamartomas only form in cells where the second (normal) copy is also lost by a somatic mutation. This explains why hamartomas are scattered and focal — not every cell undergoes the second hit. The earlier and more frequently these second-hit events occur in a developing brain, the more tubers form, and the more severe the epilepsy and cognitive outcome tend to be.

Genetic testing identifies a pathogenic variant in TSC1 or TSC2 in approximately 85% of people with clinically definite TSC. In the remaining 15%, the mutation may be present in only a subset of cells (somatic mosaicism) or may lie in a gene region not yet captured by standard sequencing panels. A negative genetic test does not rule out TSC if the clinical criteria are met.

Back to Table of Contents

Brain Manifestations: Tubers, Nodules, and Astrocytomas

The brain is the organ most central to suffering in TSC. Nearly all affected individuals have brain involvement, and the neurological consequences — seizures, cognitive impairment, autism, behavioral problems — dominate daily life for patients and families. Three distinct types of brain lesion characterize TSC:

Cortical Tubers

Cortical tubers are the defining brain lesion of TSC and the origin of the disease's name (tuber = potato-like lump in Latin). They are focal regions of the brain cortex where normal neuronal development went wrong — producing areas of disorganized, dysplastic (abnormally developed) cortex containing abnormally large neurons and distinctive "giant cells." On MRI, tubers appear as bright spots in the cortex, and over time they may calcify.

Virtually every person with TSC has multiple cortical tubers. The total number of tubers — and their location in the brain — is one of the strongest predictors of how severe the epilepsy and intellectual disability will be. Tubers in certain eloquent areas (regions governing language, movement, or vision) carry particular consequences. Children with a higher tuber count tend to have earlier seizure onset, more drug-resistant epilepsy, and lower cognitive function.

Cortical tubers are the primary seizure-generating zones in TSC. Because they contain abnormal neurons that fire chaotically, they are epileptogenic foci. When a tuber can be precisely localized and safely resected surgically, epilepsy surgery can be curative — and the earlier this is done in childhood, the better the cognitive outcome.

Subependymal Nodules (SEN)

Subependymal nodules are calcified bumps that line the walls of the lateral ventricles (the fluid-filled chambers inside the brain). On MRI they look like "candle drippings" along the ventricular surface — a classic radiological description that is essentially diagnostic of TSC. SEN are present in virtually all people with TSC and are stable — they do not grow. They do not cause problems in themselves and require no treatment. However, they must be distinguished from a closely related but far more dangerous lesion: the subependymal giant cell astrocytoma (SEGA).

Subependymal Giant Cell Astrocytomas (SEGA)

SEGAs arise from subependymal nodules, typically near the foramen of Monro — the narrow channel connecting the lateral ventricle to the third ventricle. SEGAs grow slowly, and they develop in 5–20% of people with TSC, most commonly during childhood and adolescence. The danger is not that SEGAs are malignant (they are not) but that their location is catastrophic if they grow large enough. A SEGA at the foramen of Monro can obstruct the flow of cerebrospinal fluid, causing obstructive hydrocephalus — a dangerous buildup of fluid pressure inside the skull that, if untreated, leads to brain herniation and death.

Because SEGA growth is slow and initially silent, regular brain MRI surveillance is essential throughout childhood — typically every one to three years — to catch SEGAs before they cause acute symptoms. Treatment options include:

Symptoms of SEGA growth that families must recognize include worsening headaches (especially in the morning), vomiting, declining school performance, increasing seizure frequency, or any acute change in behavior or consciousness — these warrant urgent evaluation.

Back to Table of Contents

Epilepsy and Infantile Spasms

Epilepsy is the most common and, for many families, the most devastating aspect of TSC. 80 to 90% of people with TSC develop seizures at some point in their lives, often beginning in infancy. The seizures arise from cortical tubers, which generate abnormal electrical discharges that spread through surrounding brain tissue.

Infantile Spasms (West Syndrome)

The earliest and most alarming seizure type in TSC is infantile spasms, which affect approximately 30% of TSC infants. Infantile spasms are a severe epileptic syndrome (also called West syndrome) in which a baby has brief, sudden, symmetrical jerks — typically the arms flying out and the body jackknifing forward — occurring in clusters, often when waking from sleep. They typically begin between 3 and 12 months of age.

Infantile spasms in TSC are a neurological emergency. Without rapid, effective treatment, infantile spasms cause devastating and irreversible neurodevelopmental regression — a baby who was meeting developmental milestones may lose skills, stop making eye contact, and develop long-term intellectual disability and autism. The earlier infantile spasms are controlled, the better the developmental outcome.

Critically, TSC is one of the few conditions where the choice of seizure medication for infantile spasms genuinely matters. Vigabatrin (Sabril) is the drug of choice for infantile spasms in TSC — evidence from multiple studies, including a Cochrane review, shows that vigabatrin produces better developmental outcomes in TSC-associated infantile spasms than the standard treatment ACTH used in other causes of infantile spasms. The FDA has approved vigabatrin specifically for infantile spasms. The main side effect of vigabatrin is irreversible peripheral visual field constriction with long-term use, requiring regular ophthalmology monitoring — but in the context of TSC infantile spasms, the benefit almost always outweighs this risk.

Focal and Multifocal Seizures

Beyond infantile spasms, people with TSC experience a wide variety of seizure types: focal onset aware and impaired-awareness seizures (previously called "partial" seizures), focal to bilateral tonic-clonic seizures, atonic seizures (sudden falls), tonic seizures, and absence-like events. Because multiple cortical tubers may each generate seizures independently, seizures in TSC are often multifocal — arising from different locations at different times — which makes them particularly challenging to control with medications.

Drug-resistant epilepsy (failure of two or more appropriate antiseizure medications) occurs in a substantial proportion of TSC patients. For these individuals, the options include epilepsy surgery (resecting the most active tuber), vagus nerve stimulation (VNS), the ketogenic diet, and now everolimus as an add-on antiseizure treatment.

TSC-Associated Neuropsychiatric Disorders (TAND)

The brain effects of TSC extend far beyond seizures. Intellectual disability affects approximately 50% of people with TSC, ranging from mild to severe. Autism spectrum disorder (ASD) affects 25–50% — one of the highest rates of ASD in any genetic condition. ADHD is very common. Anxiety, mood disorders, obsessive-compulsive behaviors, and sleep disturbances are frequent. These difficulties, collectively called TSC-Associated Neuropsychiatric Disorders (TAND), are often the primary determinants of quality of life and family burden — even in people whose seizures are well controlled. TAND screening and support should be a routine part of TSC care.

Back to Table of Contents

Skin Features: Diagnosis You Can See

The skin manifestations of TSC are clinically invaluable because they are visible, highly specific, and often present from infancy — long before neurological symptoms develop. A careful skin examination under both normal and ultraviolet (Wood's lamp) light is one of the simplest and most powerful TSC diagnostic tools available. Several skin findings are among the major diagnostic criteria for the condition.

Hypomelanotic Macules (Ash-Leaf Spots)

Hypomelanotic macules — commonly called ash-leaf spots because of their characteristic oval or lance-shaped outline — are white or pale patches of skin present from birth due to reduced melanin pigment in those areas. They are the earliest visible sign of TSC, often detectable in the newborn nursery before any seizure or other symptom has appeared. Three or more hypomelanotic macules is a major diagnostic criterion for TSC.

In fair-skinned individuals, ash-leaf spots can be subtle and difficult to see under normal room light. Wood's lamp examination — shining ultraviolet light on the skin in a darkened room — makes the hypopigmentation dramatically visible by causing normal skin to fluoresce while the depigmented patches remain dark. Any infant presenting with infantile spasms should receive a Wood's lamp skin exam, since the detection of ash-leaf spots may clinch the TSC diagnosis and guide genetic testing and MRI.

Facial Angiofibromas

Facial angiofibromas are pink-to-red papules (small raised bumps) distributed in a butterfly pattern across the nose, cheeks, and chin. They are composed of overgrown blood vessels and fibrous tissue — not acne, and not related to sebaceous glands despite their historical misnomer "adenoma sebaceum." Angiofibromas typically appear between ages 2 and 5 and worsen progressively through adolescence and adulthood. They are highly distinctive and pathognomonic (virtually diagnostic) of TSC in the right context.

Treatment options include topical rapamycin (everolimus) cream, which reduces the size and redness of angiofibromas and prevents new lesion development — an elegant direct application of the same mTOR biology that drives the systemic disease. Laser ablation is used for established lesions. Neither treatment cures angiofibromas permanently; ongoing maintenance is needed.

Shagreen Patch

A shagreen patch is a connective tissue nevus — a raised, rough-textured, orange-peel or leather-like plaque, usually located on the lower back. It reflects disordered collagen organization in the dermis. Shagreen patches are present in roughly 50% of people with TSC and constitute a major diagnostic criterion.

Fibrous Cephalic Plaques

Fibrous cephalic plaques are raised, flesh-colored or yellowish-brown plaques on the forehead or scalp. They are highly specific for TSC and represent another major diagnostic criterion. Like other TSC skin lesions, they reflect hamartomatous overgrowth of fibrous tissue in the skin.

Periungual and Subungual Fibromas (Koenen Tumors)

Periungual fibromas — also called Koenen tumors — are flesh-colored fleshy growths arising from or around the nail beds of the toes and fingers. They typically appear in adolescence and adulthood and grow outward from under or alongside the nail. They are pathognomonic for TSC when found. Larger fibromas can damage the nail plate and cause pain. Treatment is surgical removal, though recurrence is common.

Confetti Lesions

Confetti lesions are multiple tiny (1–3 mm) white hypopigmented macules scattered over the arms and legs, resembling scattered confetti. They represent a minor diagnostic criterion for TSC and tend to be easier to see under Wood's lamp examination.

Back to Table of Contents

Cardiac, Renal, and Pulmonary Involvement

TSC affects organs well beyond the brain and skin. Heart, kidney, and lung involvement each carries its own specific risks and management requirements. Understanding these manifestations matters both for surveillance and for recognizing when intervention is needed before a complication becomes life-threatening.

Cardiac Rhabdomyomas

Cardiac rhabdomyomas are benign tumors of cardiac muscle (myocytes) that are present in 50–65% of newborns with TSC. They are detectable on fetal ultrasound or echocardiography and are in fact one of the most common reasons TSC is first suspected — a fetal or neonatal echocardiogram showing cardiac rhabdomyoma should prompt TSC evaluation and genetic testing.

The remarkable characteristic of cardiac rhabdomyomas is that the vast majority regress spontaneously during the first years of life without any treatment. As mTOR signaling normalizes with post-natal tissue maturation, many tumors shrink or disappear entirely. Only a minority of rhabdomyomas are large enough or strategically positioned to cause arrhythmias, ventricular outflow obstruction, or hydrops in the fetus or newborn. If symptomatic, everolimus has been shown to shrink rhabdomyomas rapidly. Surgical removal is rarely required. Wolff-Parkinson-White syndrome (an arrhythmia-causing electrical pathway abnormality) has an increased association with TSC cardiac rhabdomyomas and warrants ECG monitoring.

Renal Angiomyolipomas (AML)

Renal angiomyolipomas (AML) are the most significant renal manifestation of TSC, occurring in 70–80% of patients. These benign tumors — composed of abnormal blood vessels, smooth muscle, and fat — grow bilaterally (in both kidneys) and multiply over years. On CT or MRI, the fat component makes AMLs recognizable and distinguishable from renal cell carcinoma.

The key clinical danger of AMLs is spontaneous hemorrhage. Angiomyolipomas contain abnormal, fragile blood vessels that lack the structural support of normal vasculature. When an AML grows larger than 4 centimeters in diameter, the risk of spontaneous rupture and hemorrhage rises substantially — and a hemorrhaging AML can cause life-threatening retroperitoneal bleeding. For this reason, AMLs exceeding 4 cm should be treated prophylactically with selective embolization (blocking the blood supply to the tumor radiologically) before hemorrhage occurs. Everolimus significantly reduces AML volume and halts growth, making it an effective medical alternative or complement to embolization.

Nephrectomy (kidney removal) should be avoided whenever possible in TSC, because bilateral multiple AMLs mean that aggressive surgical intervention risks leaving patients with insufficient kidney tissue. Renal cysts also occur in 30–40% of TSC patients and are usually benign. However, patients who have a large contiguous deletion spanning both the TSC2 gene and the adjacent PKD1 gene (which causes autosomal dominant polycystic kidney disease) develop a severe, early-onset polycystic kidney phenotype that can lead to renal failure in childhood. Renal cell carcinoma risk is slightly elevated in TSC, requiring annual surveillance imaging.

Pulmonary Lymphangioleiomyomatosis (LAM)

Lymphangioleiomyomatosis (LAM) is a lung disease caused by the proliferation of abnormal smooth muscle cells — "LAM cells" — that infiltrate the lungs and destroy normal lung architecture, creating multiple thin-walled cysts throughout both lung fields. LAM occurs almost exclusively in females and is strongly estrogen-driven, typically presenting in women of reproductive age.

In TSC, LAM occurs in approximately 30–40% of adult women with the condition, often remaining subclinical and discovered only on CT screening. Symptomatic LAM causes progressive breathlessness on exertion, recurrent pneumothorax (collapsed lung — often bilateral and recurrent, requiring pleurodesis), and occasionally chylothorax (lymphatic fluid in the chest). LAM can also occur in women without TSC (sporadic LAM), also driven by somatic TSC2 mutations in LAM cells.

The pivotal MILES trial demonstrated that sirolimus (Rapamune) stabilizes lung function in LAM — preventing the progressive FEV1 decline — and the FDA approved sirolimus for LAM treatment in 2015. This was a landmark for TSC research, proving that mTOR inhibition can halt organ damage caused by TSC pathway mutations outside the original TSC genetic context. LAM monitoring and management should involve a pulmonologist familiar with the disease. Pneumothorax in a young woman — especially bilateral or recurrent — warrants CT chest and TSC/LAM evaluation.

Eye: Retinal Hamartomas

Retinal astrocytic hamartomas are white or calcified (mulberry-shaped) lesions on the retina visible on fundoscopic examination. They occur in 30–50% of TSC patients and are usually asymptomatic and non-progressive. Rarely, large or strategically placed hamartomas cause visual disturbance. Ophthalmology examination is part of the standard TSC evaluation and surveillance.

Back to Table of Contents

Diagnosis: Clinical Criteria and Testing

TSC is diagnosed by a combination of clinical findings, neuroimaging, and genetic testing. The 2012 International TSC Consensus Conference established the current diagnostic framework, which categorizes findings into major and minor criteria and defines diagnostic certainty levels.

Clinical Diagnostic Criteria

A definite diagnosis of TSC requires either:

Major criteria include: hypomelanotic macules (3 or more, at least 5 mm in diameter), facial angiofibromas (3 or more) or fibrous cephalic plaque, ungual fibromas (2 or more), shagreen patch, retinal hamartomas, cortical dysplasias (tubers or radial migration lines on MRI), subependymal nodules, subependymal giant cell astrocytoma, cardiac rhabdomyoma, lymphangioleiomyomatosis, and renal angiomyolipoma (2 or more).

Minor criteria include: "confetti" skin lesions, dental enamel pits (3 or more), intraoral fibromas (2 or more), retinal achromic patch, multiple renal cysts, and nonrenal hamartomas.

Finding a pathogenic mutation in TSC1 or TSC2 on genetic testing is itself sufficient to establish a definite diagnosis, independent of clinical criteria. A negative genetic result does not exclude TSC.

Key Diagnostic Tests

Prenatal and Family Screening

Because TSC is autosomal dominant, first-degree relatives of a newly diagnosed patient should be clinically evaluated for TSC features. When a fetal cardiac rhabdomyoma is detected on prenatal ultrasound — which is often the presenting finding that leads to TSC suspicion — genetic testing of both fetus and parents is recommended. Prenatal genetic testing (CVS or amniocentesis) is available for families with a known TSC1 or TSC2 mutation.

Back to Table of Contents

mTOR Inhibitors: Everolimus and Sirolimus

The identification of the TSC1–TSC2–mTOR pathway as the molecular basis of TSC opened the door to a class of drugs that could, for the first time, actually address the underlying biology of the disease rather than just managing its symptoms. These drugs — mTOR inhibitors (mTORi) — block the very enzyme whose overactivation causes hamartoma growth throughout the body.

Everolimus (Afinitor)

Everolimus is an oral mTOR inhibitor (an analogue of sirolimus/rapamycin) with three separate FDA-approved indications in TSC:

  1. TSC-associated SEGA — FDA-approved based on the EXIST-1 trial (Franz et al., 2013), which showed that everolimus reduced SEGA volume by ≥50% in the majority of treated patients compared to placebo. This has largely replaced surgery as first-line treatment for growing SEGAs that are not acutely causing hydrocephalus.
  2. TSC-associated renal angiomyolipoma — FDA-approved based on the EXIST-2 trial (Bissler et al., 2013), demonstrating significant and durable AML volume reduction, preventing the growth that leads to hemorrhage risk.
  3. TSC-associated focal onset seizures — FDA-approved based on the EXIST-3 trial, which showed everolimus as an add-on antiseizure medication reduced seizure frequency by 50% or more in a significant proportion of patients with drug-resistant TSC epilepsy.

Everolimus works by binding to FKBP12 protein, which then inhibits mTORC1 — directly compensating for the loss of TSC1/TSC2 suppression. The result is reduced cellular protein synthesis, reduced cell growth and division, and shrinkage of existing hamartomas combined with suppression of new growth.

Common side effects of everolimus include stomatitis (painful mouth sores — the most troublesome side effect for many patients), increased susceptibility to infections, hyperlipidemia (elevated cholesterol and triglycerides), pneumonitis (lung inflammation — requires monitoring), impaired wound healing, and rash. Regular blood level monitoring and dose adjustments are needed. Because everolimus suppresses immune function, live vaccines should be avoided during treatment.

Topical everolimus cream for facial angiofibromas has been studied in multiple trials and is effective at reducing angiofibroma size, redness, and skin texture abnormalities. It is used as a maintenance treatment, typically applied several times weekly, to control cosmetically and socially distressing facial lesions.

Sirolimus (Rapamune)

Sirolimus (rapamycin) — the parent compound — has an FDA-approved indication specifically for lymphangioleiomyomatosis (LAM), based on the MILES trial (McCormack et al., 2011). In that landmark study, sirolimus stabilized lung function (FEV1), improved quality of life, and reduced serum VEGF-D levels in patients with LAM. It is used as long-term maintenance therapy in LAM patients with abnormal or declining pulmonary function. Sirolimus is also used off-label in TSC for AML management in some centers, though everolimus has the formal FDA approval for this indication.

Treatment Decisions

The decision to start systemic mTOR inhibitor therapy in TSC requires weighing the specific organ complications present, their severity, and the patient's overall health. Everolimus treatment is generally continued long-term, as hamartomas tend to regrow when treatment is stopped — a phenomenon documented in both SEGA and AML studies. Patients and families should understand that mTOR inhibitors are not curative but disease-modifying: they control growth while treatment continues.

Back to Table of Contents

Seizure Management and Epilepsy Surgery

Epilepsy management is at the center of TSC care, particularly in childhood. The approach combines antiseizure medications, mTOR inhibition, dietary therapy, neuromodulation, and in carefully selected cases, epilepsy surgery. The goal is not just seizure reduction but — especially in young children — minimizing the neurodevelopmental damage caused by ongoing seizure activity.

Antiseizure Medications

For infantile spasms in TSC: vigabatrin is the evidence-based first choice (superior to ACTH in TSC-specific trials). ACTH may be added if vigabatrin alone is insufficient. Early, aggressive treatment of infantile spasms is associated with better long-term developmental outcomes — this is one of the most time-sensitive treatment decisions in pediatric neurology.

For focal and other seizure types: TSC epilepsy often requires multiple antiseizure medications. Commonly used agents include carbamazepine, oxcarbazepine, levetiracetam, lamotrigine, topiramate, clobazam, valproate, and others. No single medication is uniformly effective in TSC, and polytherapy is often necessary. Drug-resistant epilepsy — defined as failure of two or more appropriately chosen and dosed antiseizure medications — affects many TSC patients and triggers consideration of alternative approaches.

Everolimus as Add-On Antiseizure Therapy

The EXIST-3 trial established everolimus as a legitimate antiseizure add-on therapy in TSC patients with drug-resistant focal seizures. Approximately 40% of patients on higher-dose everolimus achieved a ≥50% reduction in seizure frequency. Everolimus addresses the biological cause of tuber excitability — mTOR hyperactivation disrupts normal synaptic organization and promotes hyperexcitability in tuber neurons — rather than just suppressing neuron firing nonspecifically as standard AEDs do.

Epilepsy Surgery

For TSC patients with drug-resistant epilepsy where one (or a limited number of) cortical tuber is identified as the primary seizure-generating zone, epilepsy surgery — surgical resection of the epileptogenic tuber(s) — can achieve dramatic results. Up to 50% of carefully selected TSC patients become seizure-free after surgery. The key is precise localization of the most active epileptogenic tuber using combined MRI, EEG (including intracranial EEG), PET scanning, and magnetoencephalography (MEG).

The earlier epilepsy surgery is performed in infancy or early childhood, the greater the cognitive and developmental benefit — because ongoing seizures in the developing brain cause progressive neurological harm. Modern TSC epilepsy surgery programs achieve excellent outcomes when cases are carefully selected at specialized centers.

Vagus Nerve Stimulation (VNS) and the Ketogenic Diet

Vagus nerve stimulation — a surgically implanted device that sends electrical impulses to the brain via the vagus nerve — reduces seizure frequency in approximately 50% of TSC patients who undergo implantation, though complete seizure freedom is uncommon. It is a reasonable option when medications have failed and surgery is not feasible.

The ketogenic diet — a high-fat, very-low-carbohydrate, protein-controlled diet that shifts the brain to using ketone bodies as fuel — has demonstrated efficacy in TSC-associated epilepsy, particularly in young children. It is resource-intensive and requires close nutritional monitoring but can dramatically reduce seizure burden in some patients.

Back to Table of Contents

Surveillance and Monitoring Protocol

Because TSC affects multiple organs in ways that evolve over time, systematic surveillance is essential throughout life. The 2012 International TSC Consensus Conference published detailed surveillance recommendations that have become the standard of care. The monitoring schedule is most intensive in childhood, when many complications first emerge, but continues into adulthood.

Brain and Neurological Surveillance

Renal Surveillance

Pulmonary Surveillance

Cardiac Surveillance

Skin, Eye, and Dental

Genetic Counseling

Every person with TSC should be offered genetic counseling. Because the condition is autosomal dominant, each biological child of an affected individual has a 50% chance of inheriting the mutation. Testing of apparently unaffected parents when a child has TSC is essential — parental mosaicism (where a parent carries the mutation in only a fraction of their cells) can be missed on standard testing but still confers transmission risk to subsequent children. Prenatal diagnosis via chorionic villus sampling or amniocentesis, and preimplantation genetic testing for families using IVF, are available options.

Back to Table of Contents

Key Research Papers

  1. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–1315. PMID 8269512
  2. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805–808. PMID 9242607
  3. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115(5):577–590. PMID 14651849
  4. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–668. PMID 18722871
  5. Northrup H, Krueger DA; International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol. 2013;49(4):243–254. PMID 24053982
  6. Krueger DA, Franz DN, Agricola K, et al. Everolimus long-term safety and efficacy in individuals with tuberous sclerosis complex. J Neurol Sci. 2018;386:100–108. PMID 29406997
  7. Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–132. PMID 23158522
  8. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824. PMID 23312829
  9. Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol. 2018;22(5):738–748. PMID 29909991
  10. Jansen FE, Braams O, Vincken KL, et al. Overlapping neurological and cognitive phenotypes in patients with TSC1 or TSC2 mutations. Neurology. 2008;70(12):908–915. PMID 18032743
  11. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–1606. PMID 21410393
  12. Capal JK, Bernardino-Cuesta B, Horn PS, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70(Pt A):245–252. PMID 28434839

For additional literature, search PubMed: tuberous sclerosis complex, PubMed: TSC mTOR inhibitor, PubMed: tuberous sclerosis epilepsy vigabatrin, or PubMed: lymphangioleiomyomatosis sirolimus.

Back to Table of Contents

Back to Table of Contents

Connections

Back to Table of Contents